Alkem Laboratories Ltd
ALKEMAlkem Laboratories Ltd
ALKEMPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
31.96 | 6.33 | 0.71% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast from 19 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
Investor Presentation
View olderÂPeers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 5,164.55 | 5,799.54 | 6,516.59 | 7,444.89 | 8,448.58 | 9,098.22 | 10,796.84 | 11,815.34 | 12,978.42 | 13,142.78 | ||||||||||
Raw Materials | 2,068.32 | 2,511.13 | 2,477.74 | 2,941.33 | 3,574.89 | 3,832.30 | 4,715.77 | 4,444.47 | 4,923.46 | 10,298.97 | ||||||||||
Power & Fuel Cost | 66.33 | 86.34 | 112.64 | 121.48 | 130.14 | 129.95 | 162.96 | 163.94 | 162.58 | |||||||||||
Employee Cost | 861.08 | 1,003.85 | 1,191.64 | 1,362.46 | 1,505.49 | 1,621.03 | 1,962.71 | 2,131.35 | 2,201.01 | |||||||||||
Selling & Administrative Expenses | 879.56 | 1,014.86 | 1,175.61 | 1,288.44 | 1,412.40 | 1,224.58 | 1,722.20 | 2,163.71 | 2,163.46 | |||||||||||
Operating & Other expenses | 196.30 | 72.40 | 434.62 | 528.71 | 248.05 | 114.76 | 32.59 | 1,189.32 | 1,093.07 | |||||||||||
EBITDA | 1,092.96 | 1,110.96 | 1,124.34 | 1,202.47 | 1,577.61 | 2,175.60 | 2,200.61 | 1,722.55 | 2,434.84 | 2,843.81 | ||||||||||
Depreciation/Amortization | 93.31 | 101.17 | 143.03 | 193.18 | 252.76 | 274.58 | 303.96 | 310.42 | 299.30 | 312.38 | ||||||||||
PBIT | 999.65 | 1,009.79 | 981.31 | 1,009.29 | 1,324.85 | 1,901.02 | 1,896.65 | 1,412.13 | 2,135.54 | 2,531.43 | ||||||||||
Interest & Other Items | 71.24 | 45.16 | 55.33 | 54.63 | 65.06 | 58.92 | 52.37 | 107.36 | 112.41 | 109.57 | ||||||||||
PBT | 928.41 | 964.63 | 925.98 | 954.66 | 1,259.79 | 1,842.10 | 1,844.28 | 1,304.77 | 2,023.13 | 2,421.86 | ||||||||||
Taxes & Other Items | 186.82 | 72.60 | 295.04 | 194.15 | 132.72 | 257.08 | 198.66 | 320.60 | 227.36 | 299.54 | ||||||||||
Net Income | 741.59 | 892.03 | 630.94 | 760.51 | 1,127.07 | 1,585.02 | 1,645.62 | 984.17 | 1,795.77 | 2,122.32 | ||||||||||
EPS | 62.02 | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 177.50 | ||||||||||
DPS | 12.70 | 15.00 | 13.00 | 16.00 | 25.00 | 30.00 | 34.00 | 50.00 | 40.00 | 40.00 | ||||||||||
Payout ratio | 0.20 | 0.20 | 0.25 | 0.25 | 0.27 | 0.23 | 0.25 | 0.61 | 0.27 | 0.23 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alkem Laboratories Ltd | 37.77 | 6.33 | 0.71% |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare ALKEM with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 1.08%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alkem Laboratories Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
ICICI Prudential Large & Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8533% | Percentage of the fund’s portfolio invested in the stock 3.38% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/119 (+1) |
ICICI Prudential Multi-Asset Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8433% | Percentage of the fund’s portfolio invested in the stock 1.13% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 59/213 (+1) |
Axis Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7593% | Percentage of the fund’s portfolio invested in the stock 1.72% | Change in the portfolio weight of the stock over the last 3 months 0.33% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/113 (+8) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Alkem Laboratories Ltd
Events
Dividend Trend
No Trend In Dividends
ALKEM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.71%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.05 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 9, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Aug 9, 2024
Cash Dividend
Ex DateEx DateFeb 16, 2024
Dividend/Share
₹35.00
Ex DateEx Date
Feb 16, 2024
Cash Dividend
Ex DateEx DateAug 10, 2023
Dividend/Share
₹10.00
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateFeb 17, 2023
Dividend/Share
₹25.00
Ex DateEx Date
Feb 17, 2023
Cash Dividend
Ex DateEx DateFeb 17, 2023
Dividend/Share
₹15.00
Ex DateEx Date
Feb 17, 2023
Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5721.55, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Alkem Laboratories Ltd has dropped around 1.32% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 82592 shares today, compared to the daily average of 5.98 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 5751.2, up 1.67% on the day. Alkem Laboratories Ltd is up 24.03% in last one year as compared to a 16.91% spurt in NIFTY and a 38.53% spurt in the Nifty Pharma index.The PE of the stock is 31.19 based on TTM earnings ending September 24.Powered by Capital Market - Live
Net profit of Alkem Laboratories rose 10.98% to Rs 688.64 crore in the quarter ended September 2024 as against Rs 620.52 crore during the previous quarter ended September 2023. Sales declined 0.74% to Rs 3414.67 crore in the quarter ended September 2024 as against Rs 3440.17 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3414.673440.17 -1 OPM %22.0521.71 - PBDT859.17779.60 10 PBT780.26705.70 11 NP688.64620.52 11 Powered by Capital Market - Live
Alkem Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 5383.3, down 2.18% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Alkem Laboratories Ltd has eased around 13.89% in last one month.Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 1.8 lakh shares today, compared to the daily average of 1.92 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 5426, down 1.11% on the day. Alkem Laboratories Ltd jumped 23.9% in last one year as compared to a 20.25% rally in NIFTY and a 40.48% spurt in the Nifty Pharma index.The PE of the stock is 31.15 based on TTM earnings ending June 24.Powered by Capital Market - Live
Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate 'SON-080' for the treatment of diabetic peripheral neuropathy in India. 'SON-080' is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India.Powered by Capital Market - Live
SON-080 is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India. According to company, 'SON-080' has undergone many years of development and the previous clinical trials have generated safety data from over 200 patients. 'SON-080' has demonstrated compelling preclinical efficacy data in both diabetic peripheral neuropathy and chemotherapy induced neuropathy, including the ability to prevent the development of neuropathy and reverse established neuropathy when assessed by nerve conduction, histological integrity and sensorimotor function measurements. Dr. Akhilesh Sharma, president & chief medical officer of Alkem said, 'We are pleased to partner with Sonnet for this programme. We believe 'SON-080' is a unique asset that has demonstrated promising disease modifying potential for diabetic peripheral neuropathy with translational studies showing nerve regeneration. There is a large prevalence of diabetic peripheral neuropathy in India, which we believe underscores the need for the drug development in this territory and potential value.' Pankaj Mohan, founder & chief executive officer of Sonnet, said, 'We are excited to partner with Alkem and look forward to advancing 'SON-080' into phase 2 clinical development. We believe that Alkem is the ideal partner with significant experience and expertise.' Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company reported 90.13% jump in consolidated net profit to Rs 545.16 crore on 2.16% rise in revenue from operations to Rs 3,031.82 crore in Q1 FY25 over Q1 FY24. Shares of Alkem Laboratories slipped 3.17% to currently trade at Rs 6,090.55 on the BSE.Powered by Capital Market - Live
Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6295, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Alkem Laboratories Ltd has risen around 18.26% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 2.52 lakh shares today, compared to the daily average of 3.65 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6309.05, up 1.17% on the day. Alkem Laboratories Ltd is up 72.23% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 35.16 based on TTM earnings ending June 24.Powered by Capital Market - Live
Alkem Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 6174.95, up 2.93% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25240.45. The Sensex is at 82401.53, up 0.32%. Alkem Laboratories Ltd has gained around 16.3% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has gained around 6.75% in last one month and is currently quoting at 22878.05, up 1.61% on the day. The volume in the stock stood at 2.31 lakh shares today, compared to the daily average of 3.57 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6198, up 2.63% on the day. Alkem Laboratories Ltd is up 69.51% in last one year as compared to a 31.09% jump in NIFTY and a 54% jump in the Nifty Pharma index.The PE of the stock is 33.97 based on TTM earnings ending June 24.Powered by Capital Market - Live
Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5954.65, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25094.85. The Sensex is at 81939.19, up 0.28%. Alkem Laboratories Ltd has added around 14.47% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has added around 5.53% in last one month and is currently quoting at 22729, up 0.64% on the day. The volume in the stock stood at 1.9 lakh shares today, compared to the daily average of 3.42 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 5956.65, up 1.11% on the day. Alkem Laboratories Ltd is up 60.84% in last one year as compared to a 29.74% gain in NIFTY and a 51.27% gain in the Nifty Pharma index.The PE of the stock is 33.35 based on TTM earnings ending June 24.Powered by Capital Market - Live
Revenue from operations stood at Rs 3,031.82 crore in June 2024 quarter, registering a growth of 2.16% on YoY basis. During the quarter, India sales were at Rs 2,022.3 crore (up 6.4% YoY) while International sales stood at Rs 967.7 crore (down 4.6% YoY). US sales for Q1 FY25 stood at Rs 641.6 crore, registering a decline of 7.7% YoY. Other International Markets sales rose 2.2% to Rs 326.1 crore during the quarter. Profit before tax stood at Rs 619.36 crore in June 2024 quarter, up 75.53% from Rs 352.85 crore posted in similar quarter a year ago. During the quarter, EBITDA stood at Rs 608.6 crore, registering a growth of 56.4% YoY. EBITDA margin improved to 20.1% in Q1 FY25 as against 13.1% posted in the same period last year. R&D expenses for the quarter increased 4.58% to Rs 125.7 crore in Q1 FY25, 4.1% of total revenue from operations. As per IQVIA data, for first quarter of FY24, the company registered a growth of 8.4% YoY versus the Indian Pharmaceutical Market (IPM) which grew by 8.7% The company outperformed the IPM in antidiabetic, neuro/CNS, gastro-intestinal, dermatology, and VMN therapies, and our ranking has improved in neuro/CNS and respiratory therapies. During the quarter, the company launched 1 product in the US and received approval for 3 abbreviated new drug applications (ANDAs) from the USFDA, including one tentative approval. As of 30 June 2024, the firm had filed 176 ANDAs and 2 NDAs with the USFDA. Of these, it had received approvals for 148 ANDAs (including 14 tentative approvals) and 2 NDA. Dr Vikas Gupta, CEO, Alkem said, 'We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter. We are committed to maximising our EBITDA margin by carefully managing our product mix, controlling costs, and taking advantage of the favourable raw material pricing environment. The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business in emerging markets. During the quarter, an important development was the successful resolution of US FDA's Form 483 at the Baddi facility. At Alkem, we remain steadfast to prioritising quality and regulatory compliance.' Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. Shares of Alkem Laboratories declined 0.36% to currently trade at Rs 5,667 on the BSE.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 11.76%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 3.39% to 3.44%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 18.75%, vs industry avg of 15.27%